Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic Breast Cancer Patients

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated promising antitumor activity and tolerability in combination with trastuzumab (Herceptin(R)) in patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Data from the ongoing trial in patients with solid tumors were presented on Saturday, June 2, 2007, by Kathy Miller, M.D., Indiana University, Indianapolis, IN, in a poster, titled, "Phase 1 Trial of Alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Alvespimycin's antitumor activity is interesting given the highly refractory stage of disease of the patients in this Phase 1 trial and the drug's mechanism of action," said Clifford A. Hudis, M.D., Chief of the Breast Cancer Service, Memorial Sloan-Kettering Cancer Center, and the study's senior author. "Alvespimycin's potential to work additively or synergistically with standard chemotherapy agents suggests that it could be an important addition to the treatment paradigm for HER2-positive metastatic breast cancer."

"These encouraging Phase 1 data support our strategy to pursue alvespimycin as a potential treatment for HER2-positive metastatic breast cancer and to advance into Phase 2 trials later this year," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Kosan has the unique advantage of having two promising Hsp90 inhibitors, tanespimycin and alvespimycin, in clinical development at the same time. Both of these compounds are showing meaningful clinical benefit and a high degree of tolerabil
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:
(Date:11/19/2009)..., , ABBOTT PARK, Ill., Nov. 19 /PRNewswir...Abbott (NYSE: ABT ) as one of its Most Admired C...r. The Deal honored Abbott as its Most Admired ... strategic use of acquisitions and divestitures si...tt has reshaped its business portfolio with a focu...
(Date:11/19/2009)..., , Part of International Internet Wee...Newswire-USNewswire/ -- The U.S. Food and Drug Adm...g, international effort, called the International ...llegal actions involving medical products. ,, (...4/FDALOGO ) ,, During the effort, the FDA,s Off...
(Date:11/19/2009)..., , PRINCETON, N.J., Nov. 19 /PRNewswire...paring alternatives to traditional spinal fusion s...on to its executive management team as the Vice Pr..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...ears of clinical and regulatory experience in the ...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 1Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 2Milwaukee County Employees Retirement System 28MCERS 29 Goes Live with V3 Self Service 60668 1Milwaukee County Employees Retirement System 28MCERS 29 Goes Live with V3 Self Service 60668 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 1RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 3RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 4
...owered Blood Glucose without Pr...ed to Begin upon Ethics Approval with Results due ...OURNE, Australia, Aug. 8 Phosphagenics,Limited ("... today,announced the successful completion of a Ph...ults of the trial demonstrated the ability of the,...
...tion,(Nasdaq: IOMI ) today announced that interim...trial of its patch-based vaccine for travelers, di...ccine -- 19 elderly and 17 adult,participants -- m... elderly,subjects with weaker immune systems respo...are the number of elderly subjects (65,and older) ...
Other Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 4
(Date:11/22/2009)...ov. 21 Congressman Chak...n the United States Senate,s vote tonight to proce...: ,, "Senators Arlen Specter and Bob Casey dese...nians for casting stand-up, critical votes in the ...c Affordable Health Care Reform legislation to ful...
(Date:11/21/2009)... Nov. 21 DNC Chairman T...Senate voted to begin full debate of health insura...newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) ,... the road to enacting health insurance reform. By ...ll now have an opportunity to debate the health re...
(Date:11/21/2009)...ov. 21 Milvia Lopez, by her attorn...ntly filed suit, in Supreme Court, New York County...es that while Ms. Lopez underwent a routine transe... HOSPITAL , doctors used an HIV infected scope exp...at several hours after being discharged from the p...
(Date:11/21/2009)...n Discusses Key Provisions of Legislation, Continu...ST. CHARLES, Ill., Nov. 21 /PRNewswire-USNewswire/...ng the landmark Affordable Health Care for America... reform legislation forward, Congress has taken de...e system. Today, AARP hosted an educational forum...
(Date:11/21/2009)... NH based medical credentialing software company... form a partnerhsip with Amerinet, Inc., the leadi... will help to transform quality care within the he...) November 21, 2009 -- ISG Group, LLC, doing busin...ement with Amerinet Inc., a leading national healt...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2
...dates on the impact of,climate changes on insect-b...the importance of childhood immunizations were pre...Press Club in Washington, D.C. The news,conference...due to drug resistant bacteria., "Infectious dise...
...und what they believe to be the most accurate way ...he growing number of obese mothers, according to a...etrics and Gynecology . , Experts from the Univer...station-adjusted projection method (GAP). , The ...
...macy Directors Will Move Razadyne and Razadyne ER,...nched, According to a New Repo...9 Decision Resources, one of the,world,s leading ...lantamine) in December 2008 will,have the greatest...
... Nyer Medical Group,Inc. (Nasdaq: NYER ) announce...., ("ADCO South") its Florida Medical-Surgical div...vision, D.A.W. Inc., was awarded a two-year,contra...award was made at the conclusion of a competitive,...
... to its unparalleled content on breastfeeding with...essional articles on child, health, from allergies...., BOULDER, Colo., July 9 Breastfeeding.com, a p...fessional articles on infant, toddler, and child h...
... Licensed-Rx, one of the leading online pharma...tee customers up to 10% off all new orders placed....9, 2008 -- Licensed RX has announced its latest cu...1985060323) was released and is valid for the firs...
Other Medicine News:Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 2Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 3Health News:Research highlights problems of predicting birthweights in obese mothers 2Health News:Research highlights problems of predicting birthweights in obese mothers 3Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 2Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 3Health News:Breastfeeding.com Becomes a Premier Resource on Child Health 2
...d 3DMax mesh is a three-dimensional, anatomically ...epair. The Bard 3DMax mesh has been designed based... inguinal canal. The result is a truly unique pros...3DMax product is constructed of Bard mesh, knitted...
...a-i system combines the longest available waveleng...ient safety and efficacy. The unique flat beam pro...ic range to all targeted structures. The Lyra-I un...fety. All Lyra-I patients are protected by patente...
Surgisis® IHM™ Inguinal Hernia Matrix
...cs Ceralas D 980 nm diode laser provides controlle... most surgical procedures. Unlike other medical l...teral tissue damage or charring. The Ceralas D la...od vessels thereby minimizing inflammation and th...
Medicine Products: